Format

Send to

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2011 Jul;47(7):531-7. doi: 10.1358/dot.2011.47.7.1622076.

Vilazodone: a new treatment option for major depressive disorder.

Author information

  • 1scientific.prousjournals@thomsonreuters.com

Abstract

Vilazodone hydrochloride belongs to a new class of antidepressants-the indolalkylamines-and has dual activity as a selective serotonin reuptake inhibitor (SSRI) and as a partial agonist of the serotonin 5-HT(1A) receptor. Its antidepressant activity has been demonstrated in two 8-week, double-blind, randomized, placebo-controlled trials and in a 1-year open-label study. None of these trials compared vilazodone with existing antidepressants; however, changes in depressive symptoms after vilazodone treatment were similar to those reported for SSRIs. The most common adverse events were diarrhea and nausea, although these were mild to moderate in severity and rarely a cause for discontinuation. No important clinical changes in vital signs, laboratory values, ECG morphology and sexual function were observed or reported.

PMID:
22013560
DOI:
10.1358/dot.2011.47.7.1622076
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Support Center